6-APB
6-APB (Benzo Fury) is a synthetic stimulant-entactogen of the benzofuran class, structurally related to MDA and producing MDMA-like effects. It is not scheduled by name in the US but is prosecutable as an MDA analogue under the Federal Analogue Act; it has been linked to deaths, and products sold under this name often contain other substances.
Overview
6-APB, informally sold as 'Benzo Fury', is a synthetic entactogen and stimulant of the benzofuran class, structurally related to MDA. It was first made in research settings and emerged around 2010 as a 'legal high' sold as a research chemical, in powder, pellet, or tablet form. It never became mainstream but briefly gained popularity in club scenes before being banned in several countries.
Source: DEA; peer-reviewed literature (NIH/PMC); Wikipedia (CC-BY-SA)
Chemistry & mechanism of action
6-APB acts as a releaser and reuptake inhibitor of serotonin, dopamine, and norepinephrine, raising their levels in the brain in a manner similar to MDA and MDMA, which produces its stimulant and empathogenic effects. Like related compounds it also has activity at serotonin 5-HT2 receptors. Its agonism at the 5-HT2B receptor raises specific concern about heart-valve toxicity with repeated use, a risk shared with other 5-HT2B agonists.
Source: peer-reviewed literature (NIH/PMC); Wikipedia (CC-BY-SA)
Effects
Reported effects resemble MDMA — euphoria, emotional openness, energy, and heightened senses — often with a slower onset and longer duration, which can lead users to redose. Physical effects include raised heart rate and blood pressure, dilated pupils, jaw tension, and insomnia. Because it is little studied, its effects and risks are poorly characterized.
Source: peer-reviewed literature (NIH/PMC); Wikipedia (CC-BY-SA)
Risks & harms
6-APB has only a brief history of human use and little formal safety data, so its risks are poorly understood — an uncertainty that is itself dangerous. It has been linked to deaths in the UK and Sweden, alone and in combination. As a strong serotonin releaser it strains the cardiovascular system and can cause overheating (hyperthermia), and its long duration and slow onset invite redosing that compounds the load. Its 5-HT2B activity raises concern about heart-valve damage with repeated use. Combining it with other serotonergic drugs — SSRIs, MAOIs, other stimulants or empathogens — raises the risk of serotonin syndrome, a potentially fatal reaction. A specific market hazard: products sold as 'Benzo Fury' have on analysis contained other, sometimes more dangerous substances rather than 6-APB, and any illicit pill or powder may be adulterated, including with fentanyl. Identity and dose cannot be judged by eye. Anyone with a very high temperature, chest pain, seizures, collapse, or severe agitation needs emergency care — call 911, and Poison Control at 1-800-222-1222 can advise. This page has not yet been medically reviewed.
Source: peer-reviewed literature (NIH/PMC); SAMHSA; DEA
Legal status (US)
In the United States, 6-APB is not scheduled by name under the federal Controlled Substances Act. However, because it is structurally similar to MDA — a Schedule I substance — it can be treated as a Schedule I controlled substance under the Federal Analogue Act when intended for human consumption, exposing possession, sale, or distribution to federal prosecution. States may also impose their own controls. It is explicitly banned as a Class B drug in the UK and controlled in a number of other countries. Follow local law; consult DEA resources for specifics. This page has not yet been medically reviewed.
Source: DEA; US federal law (Federal Analogue Act, 21 U.S.C. 813); Wikipedia (CC-BY-SA)
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling — penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authorityand your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulatein the destination immediately — notthe destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
After MDMA, overheating and over-hydration are both dangerous: cool down, and sip to thirst rather than gulping water (forcing plain water can drop your blood sodium dangerously).
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown — pending review”Identity
- PubChem CID
- 9794343PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- 1-(1-benzofuran-6-yl)propan-2-aminePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C11H13NOPubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CC(CC1=CC2=C(C=C1)C=CO2)NPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- FQDAMYLMQQKPRX-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- benzofury, 6-(2-Aminopropyl)benzofuran, Benzofury, 6-APB compound, FQDAMYLMQQKPRX-UHFFFAOYSA-NPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- Unknown — pending review (no Rx/OTC label; illicit — pill visuals = FIRST-PARTY submissions only, never generated or scraped)
- Route
- Unknown — pending review
- Shape
- Unknown — pending review
- Color
- Unknown — pending review
- Imprint
- Unknown — pending review
- Score
- Unknown — pending review
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- See EMCDDA/EUDA + WHO — synthesize per jurisdictionEMCDDA / EUDA ↗ · retrieved 2026-06-18
Effects
- Effects
- Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus ↗ · retrieved 2026-06-18
Risks
- Risks
- Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus ↗ · retrieved 2026-06-18
Interactions
- Interactions
- Unknown — pending review
Dosage
Pending medical reviewer
